The Rare Responsibility: The Backbone of Life

Dear Impossible Readers,

Rare skeletal diseases, or skeletal dysplasias, are a highly varied group of genetic and metabolic disorders that impact bone formation, remodelling, mineralisation, and connective tissue health. Even though each condition is rare individually, they collectively include hundreds of different disorders with serious clinical effects, such as severe deformities, chronic pain, increasing disability, and early death. Recent advances in molecular genetics over the last twenty years have shown that these conditions are not just different versions of a single issue but stem from distinct biological failures within the skeletal system. Consequently, rare skeletal diseases offer valuable insight into the mechanisms behind human bone development and maintenance.

Five disorders exemplify distinctly different underlying mechanisms. Fibrodysplasia Ossificans Progressiva (FOP) features abnormal BMP activation due to ACVR1 mutations, leading to progressive ossification of soft tissues. Osteogenesis Imperfecta (OI) mainly results from mutations in type I collagen, leading to fragile bones with compromised structural integrity. Cleidocranial Dysplasia (CCD) is caused by mutations in the RUNX2 transcription factor, impairing osteoblast formation and skeletal development. Hypophosphatasia (HPP) involves a deficiency of tissue-nonspecific alkaline phosphatase, leading to inadequate mineralisation due to pyrophosphate accumulation. Camurati-Engelmann Disease (CED) is driven by dysregulated TGF-β signalling, leading to abnormal thickening of the cortical bone. These diseases highlight how issues in signalling pathways, extracellular matrix, development, enzyme activity, and bone remodelling can independently lead to severe skeletal disorders.

Existing treatment strategies generally target specific diseases and are often only partly effective. Managing FOP mainly involves avoiding trauma and controlling inflammatory flare-ups, with experimental therapies targeting Activin A and ACVR1 signalling currently under active research. OI is typically managed with bisphosphonates to reduce fracture risk, in combination with orthopaedic stabilisation and physical therapy. In CCD, treatments are mostly surgical and dental, focusing on correcting craniofacial and orthodontic issues. HPP has seen notable progress thanks to enzyme replacement therapy with asfotase alfa, which greatly enhances mineralisation and survival rates in severe pediatric cases. CED poses more challenges, and current treatments include corticosteroids, pain relievers, and limited immunomodulatory options to help reduce pain and inflammation.

Future therapies are shifting from supportive care to targeted molecular interventions. In FOP, therapies targeting Activin A and BMP signalling are in advanced trials. In 2025, garetosmab, a monoclonal antibody, reduced the incidence of new heterotopic ossification lesions by over 90% in Phase III trials. Palovarotene, a retinoic acid receptor-γ agonist, became the first approved disease-modifying therapy for FOP in some countries, marking a milestone. In OI, the anti-sclerostin antibody setrusumab recently demonstrated strong improvements in bone mineral density in Phase III trials, though translating that into a clear reduction in clinical fracture rates remains an ongoing hurdle. Though CRISPR-based mutation correction remains experimental, advances in gene editing and RNA therapeutics suggest mutation-specific treatments may become viable within the next decade. Overall, this progress signals a shift from symptom management to biologically targeted and potentially preventive therapies for rare skeletal diseases.

Yours Possibly

Which rare disease category would you like to see covered next?